Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients?
Author(s): Cruz DN, Mahnensmith RL, Perazella MA Affiliation(s): Department of Medicine, Yale University School of Medicine, New Haven, CT 06520-8029, USA. Publication date & source: 1997-12, Am J Kidney Dis., 30(6):772-9. Publication type: Symptomatic hypotension during hemodialysis is a disabling complication in end-stage renal disease (ESRD) patients, especially in certain groups of patients who are at higher risk for this problem. Autonomic dysfunction is thought to play a significant role. We evaluated the efficacy of midodrine, an oral agent with selective alpha-adrenergic agonist activity used in the treatment of neurogenic orthostatic hypotension, on 10 hemodialysis patients with persistent intradialytic hypotension. The patients were given a dose of midodrine (mean dose, 5.5 mg; range, 5 to 10 mg) 30 minutes before each hemodialysis session. We compared blood pressure, pulse, body weight, and laboratory values for 10 consecutive dialysis sessions off and on midodrine therapy.
